skip to content

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)

Investors

Investor updates
view all

stay updated

get the latest news and updates to your inbox.